Latest News

Phd fellowship in KU

Admission to PhD positions (full time) in President Chure Tarai-Madhesh Conservation Project isms | 19 July, 2015 20:54 Announcement for PhD positions Kathmandu University School of Sciences Admission to PhD positions (full time) in President Chure Tarai-Madhesh Conservation Project Total Number of Seats: 2   Project description: President Chure Tarai-Madhesh Conservation Development Committee Secretariat provides grant to Kathmandu Univer

New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common malignant cancer and the third leading cause of cancer death worldwide. Molecular profiling of changes in gene expression has improved our understanding of the HCC mechanism, allowing the identification of biomarkers for HCC diagnosis and HCC patient stratification for prognosis and therapy. Recently, a new group of molecules, microRNAs, has been discovered to be aberrantly expressed in HCC and some of them are functionally involved in H

BioPen to rewrite orthopaedic implants surgery

A handheld ‘bio pen’ developed in the labs of the University of Wollongong (UOW) will allow surgeons to design customised implants on-site and at the time of surgery. The BioPen, developed by researchers from the UOW-headquartered Australian Research Council Centre of Excellence for Electromaterials Science (ACES), will give surgeons greater control over where the materials are deposited while also reducing the time the patient is in surgery by delivering live cells and growth

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

The goal for developing new antimalarial drugs is to find a molecule that can target multiple stages of the parasite’s life cycle, thus impacting prevention, treatment, and transmission of the disease. The 4(1H)-quinolone-3-diarylethers are selective potent inhibitors of the parasite’s mitochondrial cytochrome bc1 complex. These compounds are highly active against the human malaria parasites Plasmodium falciparum and Plasmodium vivax. They target both the liver and blood stages of

Single-shot malaria treatment on the horizon

Early research on a new malaria drug indicates it could be effective for treating and preventing the devastating disease, says an international team of researchers. The drug, which is now undergoing Phase II clinical trials in humans, inhibits an enzyme essential to the survival of malaria. If successful, the drug could be used as part of a single dose treatment regime, they report in the journal Science Translational Medicine . "Treatments often fail because patients don'